

Joseph Lim

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7720337/publications.pdf>

Version: 2024-02-01

115
papers

6,481
citations

101496

36
h-index

66879

78
g-index

117
all docs

117
docs citations

117
times ranked

10032
citing authors

#	ARTICLE	IF	CITATIONS
1	Oral Cyanobacteria and Hepatocellular Carcinoma. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2022, 31, 221-229.	1.1	12
2	The ALT upper reference interval debate: Blame it on the alcohol. <i>Clinica Chimica Acta</i> , 2022, 526, 62-65.	0.5	0
3	NASH and the Gut Microbiome: Implications for New Therapies. <i>Clinical Liver Disease</i> , 2022, 19, 97-100.	1.0	8
4	Letter to the editor: Both universal screening and vaccination are essential components of a multipronged approach to hepatitis B elimination. <i>Hepatology</i> , 2022, 75, 1664-1666.	3.6	0
5	Non-responders to sofosbuvir/velpatasvir/voxilaprevir in the treatment of chronic hepatitis C infection. <i>Journal of Hepatology</i> , 2022, , .	1.8	0
6	Drug development of nonalcoholic fatty liver disease: challenges in research, regulatory pathways, and study endpoints. <i>Expert Opinion on Drug Discovery</i> , 2021, 16, 125-134.	2.5	3
7	AGA Clinical Practice Update on Diagnosis and Management of Immune Checkpoint Inhibitor Colitis and Hepatitis: Expert Review. <i>Gastroenterology</i> , 2021, 160, 1384-1393.	0.6	121
8	AGA Clinical Practice Update on Lifestyle Modification Using Diet and Exercise to Achieve Weight Loss in the Management of Nonalcoholic Fatty Liver Disease: Expert Review. <i>Gastroenterology</i> , 2021, 160, 912-918.	0.6	245
9	Patient-reported outcomes 12 months after hepatitis C treatment with direct-acting antivirals: Results from the PROP UP study. <i>Liver International</i> , 2021, 41, 692-704.	1.9	11
10	Trends in Hepatocellular Carcinoma Incidence and Risk Among Persons With HIV in the US and Canada, 1996-2015. <i>JAMA Network Open</i> , 2021, 4, e2037512.	2.8	26
11	Willingness to participate in research among black patients with liver disease: A national cross-sectional study. <i>Journal of Viral Hepatitis</i> , 2021, 28, 982-993.	1.0	2
12	The effect of chronic viral hepatitis on prognostic value of inflammatory biomarkers in hepatocellular carcinoma. <i>Cancer Medicine</i> , 2021, 10, 5395-5404.	1.3	0
13	Protease inhibitor-based direct-acting antivirals are associated with increased risk of aminotransferase elevations but not hepatic dysfunction or decompensation. <i>Journal of Hepatology</i> , 2021, 75, 1312-1322.	1.8	6
14	Care of the Patient With Abnormal Liver Test Results. <i>Annals of Internal Medicine</i> , 2021, 174, ITC129-ITC144.	2.0	2
15	AGA Rapid Review and Guideline for SARS-CoV2 Testing and Endoscopy Post-Vaccination: 2021 Update. <i>Gastroenterology</i> , 2021, 161, 1011-1029.e11.	0.6	29
16	Low real-world eligibility rates for nonalcoholic steatohepatitis patients for phase 3 clinical trial criteria application in a large academic health system. <i>European Journal of Gastroenterology and Hepatology</i> , 2021, 33, 424-429.	0.8	2
17	Medication Non-adherence in a Prospective, Multi-center Cohort Treated with Hepatitis C Direct-Acting Antivirals. <i>Journal of General Internal Medicine</i> , 2020, 35, 1011-1020.	1.3	16
18	Reply to: "Patient-reported symptoms during direct-acting antiviral treatment: A real-life study in HIV-HCV coinfecting patients (ANRS-AC13 HEPAVIH)". <i>Journal of Hepatology</i> , 2020, 72, 592-593.	1.8	0

#	ARTICLE	IF	CITATIONS
19	Liver fibrosis and accelerated immune dysfunction (immunosenescence) among HIV-infected Russians with heavy alcohol consumption - an observational cross-sectional study. BMC Gastroenterology, 2020, 20, 1.	0.8	26
20	Direct-Acting Antivirals Improve Overall Survival in Interventional Oncology Patients with Hepatitis C and Hepatocellular Carcinoma. Journal of Vascular and Interventional Radiology, 2020, 31, 953-960.	0.2	5
21	AGA Institute Rapid Review and Recommendations on the Role of Pre-Procedure SARS-CoV-2 Testing and Endoscopy. Gastroenterology, 2020, 159, 1935-1948.e5.	0.6	44
22	Management of Hepatitis C in Special Populations: HIV Coinfection, Renal Disease, and Decompensated Cirrhosis. Clinical Liver Disease, 2020, 16, 29-31.	1.0	5
23	Abnormal Liver Tests in COVID-19: A Retrospective Observational Cohort Study of 1,827 Patients in a Major U.S. Hospital Network. Hepatology, 2020, 72, 1169-1176.	3.6	194
24	HIV- and HCV-specific markers and echocardiographic pulmonary artery systolic pressure among United States veterans. Scientific Reports, 2020, 10, 18729.	1.6	2
25	<p>Evaluating the Therapeutic Potential of Cenicriviroc in the Treatment of Nonalcoholic Steatohepatitis with Fibrosis: A Brief Report on Emerging Data</p>. Hepatic Medicine: Evidence and Research, 2020, Volume 12, 115-123.	0.9	13
26	Prevalence of Chronic Hepatitis B Virus Infection in the United States. American Journal of Gastroenterology, 2020, 115, 1429-1438.	0.2	92
27	Waking Up the Sleeping Giant: Treatment of Hepatitis B Reactivation During Immunosuppressive Drug Therapy. Clinical Liver Disease, 2020, 16, 198-203.	1.0	1
28	AGA Institute Rapid Review of the Gastrointestinal and Liver Manifestations of COVID-19, Meta-Analysis of International Data, and Recommendations for the Consultative Management of Patients with COVID-19. Gastroenterology, 2020, 159, 320-334.e27.	0.6	330
29	AGA Rapid Recommendations for Gastrointestinal Procedures During the COVID-19 Pandemic. Gastroenterology, 2020, 159, 739-758.e4.	0.6	254
30	Budd-Chiari Syndrome. Clinics in Liver Disease, 2020, 24, 453-481.	1.0	9
31	Spotlight: COVID-19 PPE and Endoscopy. Gastroenterology, 2020, 159, 759.	0.6	9
32	Risk factors for hepatocellular carcinoma (HCC) in the northeast of the United States: results of a case-control study. Cancer Causes and Control, 2020, 31, 321-332.	0.8	20
33	FIB-4 stage of liver fibrosis is associated with incident heart failure with preserved, but not reduced, ejection fraction among people with and without HIV or hepatitis C. Progress in Cardiovascular Diseases, 2020, 63, 184-191.	1.6	25
34	AGA Clinical Practice Update on Screening and Surveillance for Hepatocellular Carcinoma in Patients With Nonalcoholic Fatty Liver Disease: Expert Review. Gastroenterology, 2020, 158, 1822-1830.	0.6	202
35	Excess Weight Gain After Cure of Hepatitis C Infection with Direct-Acting Antivirals. Journal of General Internal Medicine, 2020, 35, 2025-2034.	1.3	19
36	Pathophysiology of Hepatic Encephalopathy. Clinics in Liver Disease, 2020, 24, 175-188.	1.0	22

#	ARTICLE	IF	CITATIONS
37	DAA therapy and long-term hepatic function in advanced/decompensated cirrhosis: Real-world experience from HCV-TARGET cohort. <i>Journal of Hepatology</i> , 2020, 73, 540-548.	1.8	85
38	Assessing the Effectiveness of Strategies in US Birth Cohort Screening for Hepatitis C Infection. <i>Journal of Clinical and Translational Hepatology</i> , 2020, 8, 1-17.	0.7	8
39	Hepatitis C. <i>Gastroenterology Clinics of North America</i> , 2020, 49, 279-299.	1.0	0
40	Brief Report: Accuracy of FIB-4 for Cirrhosis in People Living With HIV and Hepatocellular Carcinoma. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2020, 85, 530-534.	0.9	0
41	Clinical Outcome Event Adjudication in a 10-Year Prospective Study of Nucleos(t)ide Analogue Therapy for Chronic Hepatitis B. <i>Journal of Clinical and Translational Hepatology</i> , 2020, 8, 1-8.	0.7	3
42	The impact of socioeconomic status on outcomes in hepatocellular carcinoma: Inferences from primary insurance. <i>Cancer Medicine</i> , 2019, 8, 5948-5958.	1.3	11
43	AGA Clinical Practice Update on Surveillance for Hepatobiliary Cancers in Patients With Primary Sclerosing Cholangitis: Expert Review. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 2416-2422.	2.4	60
44	Increasing contribution of non-alcoholic fatty liver disease to hepatocellular carcinoma incidence and mortality in U.S. Medicare. <i>Hepatobiliary Surgery and Nutrition</i> , 2019, 8, 506-508.	0.7	0
45	Non-invasive Fibrosis Assessment of Patients with Hepatitis C: Application of Society Guidelines to Clinical Practice. <i>Current Hepatology Reports</i> , 2019, 18, 249-258.	0.4	4
46	Patient-reported symptoms during and after direct-acting antiviral therapies for chronic hepatitis C: The PROP UP study. <i>Journal of Hepatology</i> , 2019, 71, 486-497.	1.8	37
47	AGA Clinical Practice Update on Interaction Between Oral Direct-Acting Antivirals for Chronic Hepatitis C Infection and Hepatocellular Carcinoma: Expert Review. <i>Gastroenterology</i> , 2019, 156, 2149-2157.	0.6	90
48	Comparison of the prevalence, severity, and risk factors for hepatic steatosis in HIV-infected and uninfected people. <i>BMC Gastroenterology</i> , 2019, 19, 52.	0.8	8
49	Prevention and Management of Hepatitis B in Healthcare Professionals. <i>Current Hepatology Reports</i> , 2019, 18, 1-8.	0.4	5
50	Impact of Direct Acting Antivirals on Survival in Patients with Chronic Hepatitis C and Hepatocellular Carcinoma. <i>Scientific Reports</i> , 2019, 9, 17081.	1.6	22
51	Regional and Rural-Urban Differences in the Use of Direct-acting Antiviral Agents for Hepatitis C Virus. <i>Medical Care</i> , 2019, 57, 279-285.	1.1	18
52	Advancing Age and Comorbidity in a US Insured Population-Based Cohort of Patients With Chronic Hepatitis B. <i>Hepatology</i> , 2019, 69, 959-973.	3.6	60
53	Status of Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection and Remaining Challenges. <i>Gastroenterology</i> , 2019, 156, 431-445.	0.6	133
54	Healthcare resource utilization and costs by disease severity in an insured national sample of US patients with chronic hepatitis B. <i>Journal of Hepatology</i> , 2019, 70, 24-32.	1.8	35

#	ARTICLE	IF	CITATIONS
55	Determinants of Liver Complications Among HIV/Hepatitis B Virusâ€“Coinfected Patients. Journal of Acquired Immune Deficiency Syndromes (1999), 2019, 82, 71-80.	0.9	14
56	Impact of direct-acting antivirals and 12-week sustained viral response on clinical outcomes in patients with hepatitis C and hepatocellular carcinoma.. Journal of Clinical Oncology, 2019, 37, 397-397.	0.8	0
57	Safety and Effectiveness of Ledipasvir and Sofosbuvir, With or Without Ribavirin, in Treatment-Experienced Patients With Genotype 1 Hepatitis C Virus Infection and Cirrhosis. Clinical Gastroenterology and Hepatology, 2018, 16, 1811-1819.e4.	2.4	20
58	An expert consensus for the management of chronic hepatitis B in Asian Americans. Alimentary Pharmacology and Therapeutics, 2018, 47, 1181-1200.	1.9	40
59	Expanding Capacity to Treat Hepatitis C: Overcoming Barriers and New Innovations. Current Hepatology Reports, 2018, 17, 83-87.	0.4	0
60	Psychometric properties of the <scp>PROMIS</scp> short form measures in a U.S. cohort of 961 patients with chronic hepatitis C prescribed direct acting antiviral therapy. Alimentary Pharmacology and Therapeutics, 2018, 47, 1001-1011.	1.9	16
61	Bilirubin Is Inversely Associated With Cardiovascular Disease Among HIVâ€“Positive and HIVâ€“Negative Individuals in VACS (Veterans Aging Cohort Study). Journal of the American Heart Association, 2018, 7, .	1.6	43
62	Prevalence and impact of baseline resistance-associated substitutions on the efficacy of ledipasvir/sofosbuvir or simeprevir/sofosbuvir against GT1 HCV infection. Scientific Reports, 2018, 8, 3199.	1.6	18
63	Practice Patterns in Hepatitis B Virus Screening Before Cancer Chemotherapy in a Major US Hospital Network. Digestive Diseases and Sciences, 2018, 63, 61-71.	1.1	13
64	Management of Chronic Hepatitis C in End-stage Renal Disease. Journal of Clinical Gastroenterology, 2018, 52, 287-294.	1.1	2
65	Future Pharmacotherapy for Non-alcoholic Steatohepatitis (NASH): Review of Phase 2 and 3 Trials. Journal of Clinical and Translational Hepatology, 2018, 6, 1-12.	0.7	49
66	A comprehensive assessment of patient reported symptom burden, medical comorbidities, and functional well being in patients initiating direct acting antiviral therapy for chronic hepatitis C: Results from a large US multi-center observational study. PLoS ONE, 2018, 13, e0196908.	1.1	23
67	Patient engagement and study design of PROP UP: A multi-site patient-centered prospective observational study of patients undergoing hepatitis C treatment. Contemporary Clinical Trials, 2017, 57, 58-68.	0.8	13
68	American Gastroenterological Association Institute Guideline on the Role of Elastography in the Evaluation of Liver Fibrosis. Gastroenterology, 2017, 152, 1536-1543.	0.6	121
69	FIBâ€“4 stage of liver fibrosis predicts incident heart failure among HIVâ€“infected and uninfected patients. Hepatology, 2017, 66, 1286-1295.	3.6	26
70	Medicaid Reimbursement for Oral Direct Antiviral Agents for the Treatment of Chronic Hepatitis C. American Journal of Gastroenterology, 2017, 112, 828-832.	0.2	47
71	American Gastroenterological Association Institute Clinical Practice Updateâ€“Expert Review: Care of Patients Who Have Achieved a Sustained Virologic Response After Antiviral Therapy for Chronic Hepatitis C Infection. Gastroenterology, 2017, 152, 1578-1587.	0.6	69
72	Developing therapies to treat hepatitis C infection in post-liver transplant recipients. Expert Opinion on Pharmacotherapy, 2017, 18, 165-174.	0.9	3

#	ARTICLE	IF	CITATIONS
73	Introduction of Clinical Practice Update Committee Articles. Clinical Gastroenterology and Hepatology, 2017, 15, 4.	2.4	4
74	ACG Clinical Guideline: Evaluation of Abnormal Liver Chemistries. American Journal of Gastroenterology, 2017, 112, 18-35.	0.2	672
75	Survival after treatment with curative intent for hepatocellular carcinoma among patients with vs without non-alcoholic fatty liver disease. Alimentary Pharmacology and Therapeutics, 2017, 46, 1061-1069.	1.9	35
76	Response to Liu et al.. American Journal of Gastroenterology, 2017, 112, 1749-1750.	0.2	0
77	Hepatocellular carcinoma in patients with non-alcoholic fatty liver disease. World Journal of Gastroenterology, 2016, 22, 8294.	1.4	81
78	Comparative efficacy of antiviral therapy in preventing vertical transmission of hepatitis B: a network meta-analysis. Liver International, 2016, 36, 634-641.	1.9	16
79	Use of transient elastography in patients with HIV-HCV coinfection: A systematic review and meta-analysis. Journal of Gastroenterology and Hepatology (Australia), 2016, 31, 1684-1693.	1.4	21
80	Prevalence of hepatitis delta infection in the United States: National Health and Nutrition Examination Survey, 1999-2012. Hepatology, 2016, 64, 681-682.	3.6	12
81	Hepatic Safety of Buprenorphine in HIV-Infected and Uninfected Patients With Opioid Use Disorder: The Role of HCV-Infection. Journal of Substance Abuse Treatment, 2016, 68, 62-67.	1.5	2
82	New Hepatitis C Drugs Are Very Costly And Unavailable To Many State Prisoners. Health Affairs, 2016, 35, 1893-1901.	2.5	63
83	Optimal timing for hepatitis C therapy in <scp>US</scp> patients eligible for liver transplantation: a cost-effectiveness analysis. Alimentary Pharmacology and Therapeutics, 2016, 44, 1090-1101.	1.9	18
84	Entecavir safety and effectiveness in a national cohort of treatment-naïve chronic hepatitis B patients in the <scp>US</scp> - the <scp>ENUMERATE</scp> study. Alimentary Pharmacology and Therapeutics, 2016, 43, 134-144.	1.9	63
85	HCV Council - critical appraisal of data: recommendations for clinical practice in a rapidly evolving therapeutic landscape. Liver International, 2016, 36, 488-502.	1.9	4
86	Effectiveness of Ledipasvir-Sofosbuvir Combination in Patients With Hepatitis C Virus Infection and Factors Associated With Sustained Virologic Response. Gastroenterology, 2016, 151, 1131-1140.e5.	0.6	199
87	Current Management of Hepatitis B in 2016. Current Hepatology Reports, 2016, 15, 266-270.	0.4	0
88	Tolerability and effectiveness of sofosbuvir and simeprevir in the post-transplant setting: systematic review and meta-analysis. BMJ Open Gastroenterology, 2016, 3, e000066.	1.1	15
89	Lower response to simeprevir and sofosbuvir in HCV genotype 1 in routine practice compared with clinical trials. BMJ Open Gastroenterology, 2016, 3, e000056.	1.1	18
90	Variation in Treatment Priorities for Chronic Hepatitis C: A Latent Class Analysis. Patient, 2016, 9, 241-249.	1.1	8

#	ARTICLE	IF	CITATIONS
91	Introduction to Clinical Practice Update Committee Articles. <i>Gastroenterology</i> , 2016, 151, 45.	0.6	0
92	Disparities in hepatitis C testing in U.S. veterans born 1945–1965. <i>Journal of Hepatology</i> , 2016, 65, 259-265.	1.8	22
93	Safety and efficacy of sofosbuvir-containing regimens in hepatitis C-infected patients with impaired renal function. <i>Liver International</i> , 2016, 36, 807-816.	1.9	270
94	Effectiveness of Simeprevir Plus Sofosbuvir, With or Without Ribavirin, in Real-World Patients With HCV Genotype 1 Infection. <i>Gastroenterology</i> , 2016, 150, 419-429.	0.6	166
95	Colitis Following Initiation of Sofosbuvir and Simeprevir for Genotype 1 Hepatitis C. <i>ACG Case Reports Journal</i> , 2016, 3, 42-44.	0.2	8
96	Treatment of Hepatitis C in Patients Undergoing Immunosuppressive Drug Therapy. <i>Journal of Clinical and Translational Hepatology</i> , 2016, 4, 206-227.	0.7	2
97	Treatment of Nonalcoholic Fatty Liver Disease: The Role of Medical, Surgical, and Endoscopic Weight Loss. <i>Journal of Clinical and Translational Hepatology</i> , 2015, 3, 230-238.	0.7	36
98	Diagnosis, Management, and Prevention of Hepatitis B Reactivation. <i>Current Hepatology Reports</i> , 2015, 14, 184-194.	0.4	0
99	Evidence-based interventions to enhance assessment, treatment, and adherence in the chronic Hepatitis C care continuum. <i>International Journal of Drug Policy</i> , 2015, 26, 922-935.	1.6	95
100	Predicting Risk of End-Stage Liver Disease in Antiretroviral-Treated Human Immunodeficiency Virus/Hepatitis C Virus-Coinfected Patients. <i>Open Forum Infectious Diseases</i> , 2015, 2, ofv109.	0.4	10
101	Emerging trends in hepatocellular carcinoma incidence and mortality. <i>Hepatology</i> , 2015, 61, 191-199.	3.6	464
102	American Gastroenterological Association Institute Guideline on the Prevention and Treatment of Hepatitis B Virus Reactivation During Immunosuppressive Drug Therapy. <i>Gastroenterology</i> , 2015, 148, 215-219.	0.6	634
103	Safety profile of boceprevir and telaprevir in chronic hepatitis C: Real world experience from HCV-TARGET. <i>Journal of Hepatology</i> , 2015, 62, 286-293.	1.8	86
104	Drug Authorization for Sofosbuvir/Ledipasvir (Harvoni) for Chronic HCV Infection in a Real-World Cohort: A New Barrier in the HCV Care Cascade. <i>PLoS ONE</i> , 2015, 10, e0135645.	1.1	59
105	Systematic review with meta-analysis: the proportion of chronic hepatitis B patients with normal alanine transaminase ≤ 40 IU/L and significant hepatic fibrosis. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 39, 349-358.	1.9	86
106	Urinary Biomarkers and Progression of AKI in Patients with Cirrhosis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2014, 9, 1857-1867.	2.2	79
107	Histologic Changes in Liver Tissue From Patients With Chronic Hepatitis B and Minimal Increases in Levels of Alanine Aminotransferase: A Meta-analysis and Systematic Review. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 1262-1266.	2.4	26
108	Advancing the science and practice of gastroenterology and hepatology. <i>BMJ Open Gastroenterology</i> , 2014, 1, e900001.	1.1	0

#	ARTICLE	IF	CITATIONS
109	Hepatic Decompensation in Antiretroviral-Treated Patients Co-Infected With HIV and Hepatitis C Virus Compared With Hepatitis C Virus Monoinfected Patients. <i>Annals of Internal Medicine</i> , 2014, 160, 369-379.	2.0	214
110	The Role of Hepatic Steatosis in Chronic Hepatitis B Infection. <i>Current Hepatitis Reports</i> , 2011, 10, 134-141.	0.3	2
111	Histologic Disease in Patients with Chronic Hepatitis B, High HBV DNA, and Normal Alanine Aminotransferase Levels. <i>Current Hepatitis Reports</i> , 2010, 9, 65-74.	0.3	3
112	Liver transplantation for alcoholic liver disease: Current concepts and length of sobriety. <i>Liver Transplantation</i> , 2004, 10, S31-S38.	1.3	111
113	Endoscopic Approach to the Treatment of Gastrointestinal Bleeding. <i>Techniques in Vascular and Interventional Radiology</i> , 2004, 7, 123-129.	0.4	19
114	Lupus cerebritis and steroid psychosis in mixed connective tissue disorder. <i>Yale Journal of Biology and Medicine</i> , 2004, 77, 63-9.	0.2	1
115	Retreatment of chronic hepatitis C virus infection. <i>Reviews in Gastroenterological Disorders</i> , 2004, 4, 97-103.	0.6	4